Nasal double DNA adjuvant induces salivary FimA-specific secretory IgA antibodies in young and aging mice and blocks Porphyromonas gingivalis binding to a salivary protein

Kenjiro Kobuchi1,3, Kosuke Kataoka2*, Yoichiro Taguchi3, Tatsuro Miyake2 and Makoto Umeda3

Abstract

Background: We previously showed that nasal administration of a combination of dendritic cell (DC) targeted DNA plasmid expressing Flt3 ligand and CpG oligodeoxynucleotides 1826 as a mucosal adjuvant (double adjuvant, DA) provoked protective immunity in the upper respiratory tract of young adult and aging mice. Here, we investigated whether the nasal DA system induces secretory (SIgA) antibodies (Abs) toward recombinant fimbrillin (rFimA) of Porphyromonas gingivalis (P. gingivalis) in the saliva of young adult and aging mice. Further, we examined the functional applicability of rFimA-specific salivary SIgA Abs.

Methods: BALB/c mice (8- or 48-week-old) were nasally immunized with rFimA plus DA three times at weekly intervals. Control mice were nasally administered rFimA alone. Saliva samples were collected 1 week after the final immunization, and were subjected to rFimA-specific ELISA. To examine the functional applicability of rFimA-specific SIgA Abs, IgA-enriched saliva samples were subjected to an inhibition assay in order to assess the numbers of P. gingivalis cells bound to the salivary protein statherin.

Results: The 8- and 48-week-old mice administered nasal rFimA plus DA showed significantly increased levels of rFimA-specific SIgA Abs in saliva and elevated numbers of CD11c+ DCs in sublingual glands (SLGs), periglandular lymph nodes (PGLNs) and submandibular glands (SMGs) and nasopharyngeal-associated lymphoid tissues (NALT) compared to mice administered rFimA alone. Further, rFimA-specific SIgA Abs-containing saliva, in which IgG Abs of 8- and 48-week-old mice administered nasal rFimA plus DA were removed, significantly inhibited binding of P. gingivalis to the salivary protein.

Conclusions: These findings show that this DA system could be an effective nasal vaccine strategy for the enhancement of P. gingivalis-specific protective immunity in the oral cavity of adolescents and older individuals.

Keywords: CpG ODN, Dendritic cells, DNA plasmid, FimA, FL gene, Nasal adjuvant, Nasal immunization, Salivary SIgA
Background

Periodontitis is one of the most prevalent infectious diseases worldwide and is characterized by the destruction of periodontal supportive tissues, including inflammation of the gingiva and alveolar bone loss, following periodontal-pathogenic bacterial infection and disturbance of host immunity. Porphyromonas gingivalis (P. gingivalis) is a Gram-negative anaerobic bacterium that forms black-pigmented colonies and is involved in the onset and progression of periodontal disease [1, 2] and multiple systemic diseases [3, 4], despite being detected in healthy people [5]. Fimbriae located on the cell surface of P. gingivalis are primarily composed of polymers of FimA protein (fimbriillin), encoded by the gene fimA [6]. It is known as a virulence factor [7], and plays an important role in colonization through its association with host tissues, including salivary proteins, and other bacteria in the oral cavity [8–10]. Moreover, it has been shown that fimA-inactivated mutants showed reduced abilities to adhere to human gingival fibroblasts and epithelial cells [11]. Recently, it has also been reported that the FimA protein elicited inflammatory responses via the TLR4/NF-kB signaling pathway in human peripheral blood mononuclear cells [12]. We also previously showed that P. gingivalis FimA protein binds specifically and rigidly to salivary statherin, a human salivary protein, in a solid phase system [13].

Nasal immunization can effectively evoke the nasopharyngeal-associated lymphoid tissues (NALT)-based immune system, which preferentially induces antigen (Ag)-specific antibody (Ab) responses in the oral cavity [14] and other mucosal tissues [15, 16]. A previous study showed that the NALT-based immune system of one-year-old mice exhibited intact mucosal immune responses when mice were administered cholera toxin as a nasal adjuvant, in contrast to the age-associate alterations in intestinal immune responses [17]. Although nasal cholera toxin is a potent mucosal adjuvant, the development of safer nasal adjuvants to induce protective Ag-specific immune responses in mucosal compartments, including the oral cavity, is needed [18, 19]. In this regard, we have shown that nasal application of a DNA plasmid encoding Flt3 ligand cDNA (pFL) preferentially expanded CD8+ CD11c+ dendritic cells (DCs) and subsequently induced IL-4-producing CD4+ T cell-mediated Ag-specific mucosal immune responses [20, 21]. Further, we showed that a nasal double adjuvant (DA) composed of pFL and CpG oligodeoxynucleotides (CpG ODN) enhanced mucosal and systemic immune responses with increased numbers of CD8+ and B220+ CD11c+ DC subsets in the nasal mucosa [22, 23].

IgA Abs are produced as the major isotype on mucosal surfaces (approximately 200 mg/L of SlgA, 2 mg/L of IgG and 1 mg/L of IgM in human whole saliva) [24], which is mainly secreted as the dimeric or polymeric form of IgA (secretory IgA, SlgA) Abs. It has been shown that the major roles of SlgA Abs are neutralization of viruses or toxins and inhibition of bacterial adherence to host mucosal and tooth surfaces [24]. It has been shown that the levels of serum IgG Abs to P. gingivalis in adult and early-onset periodontitis patients were higher compared to healthy individuals, and these Ab responses exhibited protective roles in the disease process [25]. Further, specific IgA Abs directed to periodontal-pathogenic microorganisms in the gingival crevicular fluid (GCF) played a protective role in the onset of periodontal disease [26]. Conversely, it was reported that healthy individuals possessed higher levels of serum P. gingivalis-specific IgG Abs compared to periodontal disease patients [27]. Despite these studies, the protective roles of P. gingivalis-specific IgG and IgA Abs in periodontal disease remains unclear. In this study, we examined whether nasal DA could induce SlgA Abs to rFim A of P. gingivalis in the saliva of young adult and aging mice. Further, we determined the ability of rFimA-specific SlgA Abs to block adherence of live P. gingivalis to a salivary protein. We consequently showed that nasal rFimA plus DA successfully elicits elevated levels of rFimA-specific salivary SlgA Ab responses and expands mucosal CD11c+ DCs in both young adult and aging mice. Further, IgG Ab-depleted saliva from young adult and aging mice given nasal rFimA plus DA showed significantly decreased binding of P. gingivalis to a statherin-coated plate compared to mice administered nasal rFimA alone.

Methods

Mice

Female BALB/c mice were obtained from SLC Japan, Hamamatsu, Japan. Five mice per cage were maintained in horizontal laminar flow cabinets and were provided sterile food and water as part of a specific pathogen-free facility at Osaka Dental University (Hirakata, Japan). All experiments were conducted in accordance with the guidelines provided by Osaka Dental University. All mice in this study were 8 or 48 weeks of age.

Recombinant FimA (rFimA)

The DNA plasmid vector PYT1245 (Fig. 1a) expressing FimA and anti-fimbriae rabbit serum was kindly provided by Dr. Yutaka Terao of Niigata University [28, 29]. DNA manipulations were carried out according to the manufacturer’s instructions. Escherichia coli BL21 competent cells (BioDynamics Laboratory Inc., Tokyo, Japan) were transformed with PYT1245 by the heat-shocking method and were cultured in Luria-Bertani medium supplemented with ampicillin (100 μg/mL). The supernatants from ultrasonicated E. coli BL21 transformants

Kobuchi et al. BMC Oral Health (2019) 19:188
carrying the PYT1245 plasmid (Fig. 1b, lane 2) were applied to a GST affinity column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The rFimA protein (MW; approximately 41 kDa) was eluted by cleaving the GST-rFimA fusion protein with PreScission Protease. The purified rFimA protein was electrophoresed in a 4–20% gradient SDS-PAGE gel and stained with Coomassie brilliant blue R-250. Lane 1: standard marker, Lane 2: the supernatants from the ultrasonicated transformant, Lane 3: eluted solution (1 μg) from GST affinity column, Lane 4: eluted solution (3 μg) from the GST affinity column. (c) The purity of rFimA was confirmed by western blot analysis. rFimA (5 μg) was transferred to a PVDF membrane and detected using rabbit anti-fimbriae serum (1:2000 dilution) followed by HRP-conjugated goat anti-rabbit IgG Ab and TMB substrate solution. Lane 1; protein molecular weight marker, Lane 2; purified rFimA

rFimA-specific western blotting analysis
In order to confirm the purity of rFimA, western blotting analysis (Fig. 1c) was performed using rabbit anti-FimA serum as described previously [24]. In brief, the proteins were transferred electrophoretically onto a polyvinylidene difluoride membrane (Immobilon; Millipore, Bedford, MA, USA), the membrane was incubated with anti-fimbriae rabbit serum solution (1:1000 dilution), and then incubated with HRP-conjugated goat anti-rabbit IgG Ab (SouthernBiotech, Birmingham, AL, USA). TMB substrate solution (Nakalai Tesque Inc., Kyoto, Japan) was used to reveal the positive bands. An affinity mini-column Cellufine ET clean S and L (JNC corporation, Tokyo, Japan) was used to remove endotoxin from the purified rFimA solution, and a Limulus Color KY Test Wako (Fujifilm Wako Pure Chemical Corporation, Osaka, Japan) gave a reading of less than 0.1 endotoxin units of LPS per 1μg of plasmid or rFimA.

Nasal adjuvant
The plasmid pUNO1-mFlt3LGa (pFL) consists of the pUNO1 vector plus the full-length murine FL cDNA gene (InvivoGen, San Diego, CA, USA). The plasmid was purified using the EndoFree Plasmid Giga kit (QIAGEN, Valencia, CA, USA) [20, 30]. A synthetic ODN containing CpG motif 1826 (CpG ODN) (FASMAC Co., Ltd., Kanagawa, Japan) was used as a nasal adjuvant.

Nasal immunization and sample collection
Eight- (young adult) and 48- (aging) week-old mice were nasally immunized with PBS containing 5μg of rFimA plus 50μg of pFL and 10μg of CpG ODN as mucosal adjuvant (double adjuvant, DA) three times at weekly intervals. Control mice were immunized nasally with 5μg of rFimA alone. All mice were immunized under intraperitoneal anesthesia of hydrochloric acid medetomidine (0.3 mg/kg), midazolam (4 mg/kg) and butorphanol tartrate (5 mg/kg). Plasma and saliva samples were collected 7 days after the last nasal immunization. Saliva was obtained from mice following i.p. injection of 100μg of sterile pilocarpine/PBS solution as described previously [20, 30].
Detection assays for rFimA-specific IgA ab responses
To assess rFimA-specific Ab levels, saliva and plasma samples were collected 7 days after the last immunization and were then subjected to ELISA as described previously [20, 30, 31]. Briefly, 96-well microtest assay plates (BD Biosciences, Oxnard, CA, USA) were coated with 1 μg/ml of rFimA in PBS. After incubating serial dilutions of samples, horseradish peroxidase-conjugated goat anti-mouse IgA or IgG Ab (Southern Biotechnology Associates Inc., Birmingham, AL, USA) was added to the wells. The color reaction was developed using 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate buffer for 15 min at room temperature. Endpoint titers were expressed as the reciprocal log2 of the last dilution that gave an OD415 of 0.1 greater than background. Mice were euthanized by cervical spine fracture dislocation under inhaled isoflurane anesthesia, and mononuclear cells were isolated from sublingual glands (SLGs), periglandular lymph nodes (PGLNs) and submandibular glands (SMGs) 1 week after the final immunization, and were then subjected to an enzyme-linked immunospot (ELISPOT) assay to enumerate the numbers of rFimA-specific IgA Ab-forming cells (AFCs) [20, 30–32]. In brief, mononuclear cells from SMGs and SLGs were isolated by combination of an enzymatic dissociation procedure with collagenase type IV (0.5 mg/ml; Merck KGaA, Darmstadt, Germany) followed by discontinuous Percoll® (Amersham Biosciences, Arlington Heights, IL, USA) gradient centrifugation [17, 30–32]. PGLNs were removed aseptically and the cells were then isolated using a mechanical dissociation method using gentle teasing through stainless steel screens as described previously [20, 32]. Ninety-six-well nitrocellulose plates (Millititer HA; Millipore, Bedford, MA, USA) were coated with 1 μg/ml solution of rFimA for analysis of anti-FimA-specific IgA AFCs.

Flow cytometric analysis
In order to determine the numbers of CD11c+ DCs, aliquots of mononuclear cells (2–10 X 10^5 cells) isolated from NALT, SLGs, SMG and PGLNs were stained with FITC-conjugated anti-mouse CD11c monoclonal Ab (BD Biosciences, San Jose, CA, USA). These samples were then subjected to flow cytometric analysis (FACS-Verse®; BD Biosciences) [20, 22, 30, 31]. Typical FACS plots and gating strategy are provided in Additional file 1: Figure S1.

Blocking assay for binding of live P. gingivalis 381 cells to salivary statherin
Statherin composing of 43 amino acids was artificially synthesized according to peptide sequence (FASMAC Co. Ltd., Kanagawa, Japan). Enriched saliva samples were prepared in order to determine the functionality of FimA-specific IgA Abs, IgG Ab. Saliva from 8- and 48-week-old non-immunized mice or mice immunized nasally with rFimA plus DA or rFimA alone were applied to a protein G affinity mini-column (Protein G HP SpinTrap; GE Healthcare Bio-Sciences AB) and saliva run through the column was used as the IgA-enriched saliva samples. One hundred microliters of statherin in PBS (100 μg/ml) was coated to an opaque 96-well plate, and the plate was blocked with 1% BSA in PBS after washing with PBS three times. One hundred microliters of IgA Ab enriched saliva samples (protein concentration; 1.0 mg/ml) or whole saliva was respectively mixed with 100 μL of live P. gingivalis cells (0.5 x 10^8 cells) and incubated at room temperature for 1 h. The respective mixtures were subsequently added to the statherin-coated 96-well plate, and the plate was incubated for 1 h at room temperature. After each well of the plate was washed with PBS three times, the number of live P. gingivalis cells bound to statherin of each well was assessed based on quantitation of adenosine triphosphate (ATP) from live P. gingivalis cells by luminescence measurement of luciferase using a Bac Titer-Glo Microbial cell viability assay (Promega Co., Madison, WI, USA). The number of 5 x 10^7 live cells is equivalent to 350 relative light units (RLU) of luminescence. The binding activity was calculated by subtracting the value of non-specific binding of saliva samples from 8- or 48-week-old non-immunized mice.

Statistical analysis
The data are expressed as the mean ± standard error of the mean (SEM). All mouse groups were compared to control mice with an unpaired Mann-Whitney U test using GraphPad Prism version 7 (GraphPad software, San Diego, CA, USA). p values of < 0.05 were considered statistically significant.

Results
Induction of rFimA-specific SlgA ab responses in NALT and salivary gland-associated tissues of young adult and aging mice administered rFimA plus DA
We initially examined whether nasal administration of DA would enhance rFimA-specific SlgA Ab responses in 8- and 48-week-old mice. Nasal immunization with 5 μg of rFimA plus a combination of pFL and CpG ODN resulted in significantly increased levels of salivary rFimA-specific SlgA Ab responses in 8-week-old mice compared to those in identically aged mice given nasal rFimA alone (Fig. 2). Of interest, elevated levels of salivary rFimA-specific SlgA Ab responses were also observed in 48-week-old mice nasally immunized with
rFimA plus DA, comparable to those responses seen in 8-week-old mice (Fig. 2). In contrast, rFimA-specific IgG Abs were not detected in saliva of 8- or 48-week-old mice immunized nasally with rFimA plus a combination of pFL and CpG ODN (data not shown). Upregulation of salivary rFimA-specific IgA Ab responses were further supported at the single cell level. Thus, elevated numbers of rFimA-specific IgA AFCs were detected in SLGs (Fig. 3a), SMGs (Fig. 3b) and PGLNs (Fig. 3c) of 8- and 48-week-old mice administered nasal rFimA plus DA. These results clearly show that the DA system effectively elicits rFimA-specific SIgA Ab responses in the nasal mucosa and salivary gland-associated tissues in young adult and aging mice. Notably, higher numbers of rFimA-specific IgA AFCs were detected in SLGs of 8- and 48-week-old mice (Fig. 3a) compared to those in SMGs (Fig. 3b). Since nasal immunization is known to induce systemic immunity in addition to the mucosal immune responses, rFimA-specific Ab responses in plasma and spleen were examined. Nasal rFimA plus DA elicited significantly increased levels of rFimA-specific IgG (Fig. 4a) and IgA Ab (Fig. 4b) responses in plasma and spleen (data not shown) of 8- and 48-week-old immunized mice compared to the responses of 8- and 48-week-old mice administered nasal rFimA alone. Taken together, our results show that the DA system effectively induces rFimA-specific mucosal IgA and systemic IgG and IgA Ab responses.
Increases of CD11c+ DCs in NALT and salivary gland-associated tissues with nasal rFimA plus DA
Since our previous studies showed that a combination of pFL and CpG ODN as nasal adjuvants preferentially expands CD11c+ DCs in mucosal inductive and effector tissues [22, 30], we next examined the frequency of CD11c+ DCs in the various mucosal tissues of 8- and 48-week-old mice administered rFimA plus DA. As shown in Table 1, nasal immunization of rFimA plus DA significantly increased the frequency of CD11c+ DCs in NALT, SLGs and PGLNs of 8- and 48-week-old mice administered rFimA plus DA compared to identically aged mice given rFimA alone. Interestingly, the dramatic expansion of DC populations was observed in SLGs and PGLNs as well as NALT. Taken together, these data indicate that nasal administration of rFimA plus DA preferentially expands the numbers of CD11c+ DCs in mucosal inductive and effective sites of young adult and aging mice.

Table 1 Comparison of the proportion of CD11c+ DCs in various mucosal lymphoid tissues

| Mice   | DA | NALT | SLGs | SMGs | PGLNs |
|--------|----|------|------|------|-------|
| 8 weeks| +  | 6.7 ± 1.1 * | 11.2 ± 2.5 * | 2.7 ± 1.3 | 14.1 ± 3.9 * |
|        | −  | 1.9 ± 0.3 | 4.1 ± 1.4 | 1.9 ± 0.6 | 2.5 ± 0.3 |
| 48 weeks| + | 5.9 ± 1.0 * | 9.7 ± 2.1 * | 2.5 ± 1.0 | 12.2 ± 4.1 * |
|        | − | 1.2 ± 0.4 | 2.8 ± 0.9 | 1.4 ± 0.5 | 1.9 ± 0.3 |

The proportions of CD11c+ DCs in mucosal inductive tissues (NALT), salivary glands (SLGs, SMGs) and periglandular lymph nodes (PGLNs) of mice given nasal rFimA plus a combination of pFL and CpG ODN (n = 20) or rFimA alone (n = 20) were examined. Young (8 weeks) and aging (48 weeks) mice were nasally immunized weekly for three consecutive weeks with 50 μg rFimA, 50 μg pFL, and 10 μg CpG ODN, respectively. One week after the final immunization, mononuclear cells from NALT, SLGs, SMGs and PGLNs were stained with FITC-anti-CD11c mAbs and subjected to flow cytometry analysis by FACSVerse*. *p < 0.05 when compared with immunized mice with rFimA alone

Inhibition of live P. gingivalis 381 binding to salivary statherin by rFimA-specific salivary SIgA Abs
To examine the functionality of rFimA-specific salivary SIgA Abs, a live P. gingivalis cells binding assay was performed using a statherin-coated 96-well plate. SIgA Ab enriched saliva samples from 8-week-old mice administered nasal rFimA plus DA compared to those from 8-week-old mice given nasal rFimA alone (Fig. 5). Further, enriched IgA Ab saliva samples from 48-week-old mice nasally immunized with rFimA plus DA showed reduced ATP activity, indicating a significant reduction in the number of live P. gingivalis cells bound to the statherin-coated plate (Fig. 5). In addition, whole saliva from 8- and 48-week-old mice administered nasal rFimA plus DA showed essentially the same levels of ATP activities compared to those of SIgA enriched saliva (Fig. 5). These results show that rFimA-specific salivary IgG Abs do not play a key role in preventing P. gingivalis-binding to statherin. These results show that salivary rFimA-specific IgA Abs induced by nasal immunization with rFimA plus DA effectively blocked live P. gingivalis cell binding to a salivary protein.

Discussion
Aging is a known risk factor of periodontal diseases [33] as well as various systemic diseases including atherosclerotic cardiovascular disease [34] and chronic obstructive pulmonary disease [35]. Indeed, declining immune function in mammals with increasing age affects the prevalence and severity of periodontal disease.
In this study, we examined whether nasal administration of rFimA plus a combination of pFL and CpG ODN (double adjuvant, DA) as mucosal adjuvants could induce SlgA Abs to FimA of P. gingivalis in saliva of young adult and aging mice. Further, we investigated the functionality of salivary SlgA Abs induced by nasal rFimA plus DA and live P. gingivalis cells.

Flt3 ligand (FL) is a hematopoietic growth factor that has emerged as a potential immunomodulator [36–38]. Moreover, FL has been reported to increase DC populations and enhance the Ag-presenting activity of DCs [39, 40]. We have previously shown that nasal delivery of a plasmid expressing FL cDNA (pFL) plus pneumococcal surface protein (PspA) elicited increased numbers of DCs and PspA-specific SlgA Ab responses in the nasooral cavity of young adult mice [41]. In addition, this study demonstrated that PspA-specific SlgA Abs induced by pFL as mucosal adjuvant are essential to preventing nasal carriage of Streptococcus pneumoniae [41]. Of importance, when CpG ODN, known as a TLR9 ligand, was added to pFL, this double adjuvant (DA) system potentiated mucosal and systemic immune responses to OVA [22], PspA [23, 30, 42] and influenza hemagglutinin Ag [43], mediated by the expansion and activation of CD11c+ DCs in aged mice. Based on these findings [22, 23, 30, 41, 43], we hypothesized that nasal immunization with rFimA plus DA could induce Ag-specific functional SlgA Ab responses in the oral cavity of young adult and aging mice. Our results showed remarkably enhanced levels of rFimA-specific SlgA Ab induction in saliva of aging and young adult mice administered nasal rFimA plus DA compared to age-matched mice given nasal rFimA alone (Fig. 2). In addition, significantly higher numbers of rFimA-specific IgA AFCs were seen in SLGs of mice given nasal DA (Fig. 3a) compared to another mucosal effector tissue, namely SMGs (Fig. 3b). Based upon these finding, SLGs should be considered a mucosal effector tissue in addition to SMGs, which are known as one of the major mucosal effector tissues for the production of IgA Abs in the oral cavity [32]. Thus, our study is the first to demonstrate that nasal delivery of DA induces Ag-specific IgA AFCs in SLGs, which contributes to protective immunity in the oral cavity.

As expected, nasal administration of rFimA plus DA elicited a higher frequency of CD11c+ DCs in NALT, PGLNs, SLG and SMGs of young adult and aging mice compared to mice administered rFimA alone. Among them, both NALT and PGLNs contained significantly increased numbers of DCs compared to SLGs and SMGs. These results indicate that DCs activated by nasal rFimA plus DA play an important role as Ag-presenting cells in the mucosal inductive tissues (ie., NALT and their draining lymph nodes, i.e., PGLNs) for the activation of CD4+ T cells. Thus, these effector CD4+ T cells could migrate into the mucosal effector tissues (e.g., SLGs and SMGs) to activate IgA+ B cells for their differentiation into plasma cells. We are currently investigating Th1- and Th2-type cytokine production by CD4+ T cells in both mucosal inductive and effector tissues for their contribution to the induction of Ag-specific IgA Ab responses, as previous studies reported that the DA system exhibited
a balanced Th1- and Th2-type cytokine response in both young adult and aged mice [22, 30].

Since we previously showed that *P. gingivalis* FimA protein binds specifically to a salivary statherin-coated plate [13], we next examined the interactions between live *P. gingivalis* 381 cells and rFimA-specific salivary SlgA Abs elicited by nasal rFimA plus DA in young adult and aging mice. Preincubation of *P. gingivalis* cells with enriched SlgA Abs from saliva of mice administered nasal rFimA plus DA resulted in reduced binding to statherin-coated plates (Fig. 5). These results suggest that rFimA-specific salivary SlgA Abs induced by nasal DA as mucosal adjuvant are functional and potentially inhibit the adherence of *P. gingivalis* cells to the tooth surface of young adult and aging mice.

**Conclusion**

In summary, the current study clearly shows that nasal vaccination with rFimA plus DA elicits DC-mediated rFimA-specific SlgA Ab responses in salivary young adult and aging mice. Importantly, we shed further light on rFimA-specific IgA Abs for providing effector function to prevent binding of *P. gingivalis* cells to the salivary protein statherin. These findings suggest that the nasal pFL and CpG ODN system can be an effective nasal adjuvant strategy to enhance salivary Ag-specific immunity in adolescents and older individuals. Furthermore, nasal vaccination with rFimA plus pFL and CpG ODN has potential utility in regulating *P. gingivalis*-mediated inflammatory responses in the oral cavity.

**Additional file**

Additional file 1: Figure S1. The typical FACs plot and gating strategy in SLGs and NALT. In FACs analysis, mononuclear cells from SLGs and NALT were gated to lymphocytes by using the forward- and side-scatter properties, and were subsequently analyzed for the populations of CD11c+ cells. (PPTX 4047 kb)

**Abbreviations**

Ab: Antibody; Ag: Antigen; CpG ODN: CpG oligodeoxynucleotide 1826; DCs: Dendritic cells; FL: Flt3 ligand; *P. gingivalis*: Porphyromonas gingivalis; rFimA: recombinant FimA; SlgA: Secretory-IgA

**Acknowledgements**

We are deeply grateful to Dr. Kohtaro Fujihashi at Division of Clinical Vaccinology, The International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo for the scientific discussion, critiques and editorial assistance in the preparation of the manuscript. We give thanks to Dr. Yutaka Terao at the Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, for providing the PYT1245 plasmid preparation of the manuscript. We give thanks to Dr. Yutaka Terao at the Department of Clinical Microbiology, The Institute of Medical Science, The University of Tokyo for the draft manuscript and approved the final version of the manuscript.

**Authors’ contributions**

KKataoka and MU conceived the project, designed and supervised the experiments. KKataoka, KKobuchi and YT performed all experiments, and TM analyzed the data. KKataoka wrote the draft manuscript. All authors reviewed the draft manuscript and approved the final version of the manuscript.

**Funding**

This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Numbers JP17H04424 (B) and JP17K12034 (C) from the Ministry of Education, Science, Sports and Culture of Japan. The fund covers all materials used for the research project and collection, statistical analysis, and interpretation of data.

**Availability of data and materials**

All data generated or analyzed during this study are included in this article.

**Ethics approval and consent to participate**

Animal studies were approved by the Osaka Dental University Animal Research Committee (Approval Nos. 16–07001, 17–02003 and 18–07003) and complied with the guidelines for the use of animals in research.

**Consent for publication**

Not applicable.

**Competing interests**

There are no conflicts of interest to declare.

**Author details**

1. Graduate School of Dentistry, Osaka Dental University, Hirakata, Osaka 573-1121, Japan. 2. Department of Preventive and Community Dentistry, Osaka Dental University, Hirakata, Osaka 573-1121, Japan. 3. Department of Periodontology, Osaka Dental University, Hirakata, Osaka 573-1121, Japan.

**Received**: 28 February 2019 **Accepted**: 14 August 2019

**Published online**: 19 August 2019

**References**

1. Gibbons RJ, Macdonald JB. Hemin and vitamin K compounds as required factors for the cultivation of certain strains of *Bacteroides melaninogenicus*. J Bacteriol 1960; 80:164–70.
2. Mayrand D, Holt SC. Biology of asaccharolytic black-pigmented *Bacteroides* species. Microbiol Rev 1998; 62:134–52.
3. Totaro MC, Cattani P, Fia R, Tolusso B, Ggemese E, Fedele AL, D’Onghia S, Marchetti S, Di Sante G, Canestri S, Ferrarioli G. Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. Arthritis Rheum. 2013;15:R66.
4. Serra e Silva Filho W, Casarin RC, Nicolela EL Jr, Passos HM, Sallum AW, Goncalves RB. Microbial diversity similarities in periodontal pockets and atheromatous plaques of cardiovascular disease patients. PLoS One. 2014;16:e109761.
5. Haffajee AD, Cugini MA, Tanner A, Pollack RP, Smith C, Kent RL Jr, Socransky SS. Subgingival microbiota in healthy, well-maintained elder and periodontitis subjects. J Clin Periodontol. 1998;25:346–53.
6. How KY, Song KP, Chen KG. Porphyromonas gingivalis: an overview of periodontopathogenic pathogen below the gum line. Front Microbiol. 2016.7:53.
7. Kataoka K, Amano A, Kabonwia M, Horie H, Nagata H, Shizukushi S. Active sites of saliva rich in protein for binding to *Porphyromonas gingivalis* fimbriae: Infect Immun. 1997;65:3159–64.
8. Huisman R, Costa TRD, Waksman G. A comprehensive guide to pilous biogenesis in gram-negative bacteria. Nat Rev Microbiol. 2017;15:365–79.
9. Lamont RJ, Jenkinson HF. Subgingival colonization by *Porphyromonas gingivalis*. Oral Microbiol Immuno. 2000;15:341–9.
10. Yoshimura F, Takahashi K, Nodaoka Y, Suzuki T. Purification and characterization of a novel type of fimbriae from the oral anaerobe *Bacteroides gingivalis*. J Bacteriol. 1984;160:949–57.
11. Harada S, Amano A, Kimura S, Nakagawa I, Kawabata S, Morisaki I. The importance of fimbriae in the virulence and ecology of some oral bacteria. Oral Microbiol Immunol. 1998;13:129–38.
12. Cai J, Chen J, Guo H, Pan Y, Zhang Y, Zhao W, Li X, Li Y. Recombinant fimbriae protein of *Porphyromonas gingivalis* induces an inflammatory
lot's signaling pathway in human peripheral blood mononuclear cells. Int J Mol Med. 2009;23:267–73.

13. Amano A, Kato E, Sugawara H, Kiriyama K, Ichikawa M, Nakamura T, Ohtomo A, Nakamura Y, Hara M, Takahashi H, Hara H, Hara H, Hara H. Vascular injury induced by BCG vector expressing outer surface protein A of Borella burgdorferi. Nature. 2004;433:252–5.

14. Yamanaka H, Ohara T, Hirohata T, Sato K, Hara M, Takahashi H, Hara H, Hara H, Hara H. A bacterial adjuvant for the development of mucosal vaccines. Expert Rev Vaccines. 2019;18:191–200.

15. Chong HL, Yeung PC, Lam SY, Chiu D, Lam SC, Yuen ST, et al. Effects of BCG vaccine on osteoblastic and osteoclastic cells in rodents. J Bone Miner Res. 2019;34:138–49.

16. Kataoka K, Miller CJ, Kubota M, McIntosh MB, Lohman B, Yamamoto M, Fujihashi K, Someya K, Honda M, McGhee JR, Miyake T, Fujihashi K. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55 gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in productive tissues. J Immunol. 1998;161:5952–8.

17. Hagiwara Y, McGhee JR, Fujihashi K, Kobayashi R, Yoshino N, Kataoka K, Etani Y, Kweon MN, Tamura S, Kurata T, Takeda Y, Kyono H. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissues. J Immunol. 2003;170:1754–62.

18. Langermann S, Palaszynska S, Sadzience A, Stover C, Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer surface protein A of Borella burgdorferi. Nature. 1994;372:552–5.

19. Vadas J, Davies JK, Wright PJ, Strugnell RA. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur J Immunol. 1995;25:699–75.

20. Kataoka K, Fujihashi K, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Takahashi H, Hara H, Hara H, Hara H. A bacterial adjuvant for the development of mucosal vaccines. Expert Rev Vaccines. 2009;8:1183–93.

21. Fukushima T, Sekeue S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Kreig AM, McGhee JR, Fujihashi K. A recombinant of Flt3 ligand and Cpg ODN as nasal adjuvant elicits NALT dendritic cells for enhanced mucosal immunity. J Immunol. 2006;176:121–9.

22. Kataoka K, Fujihashi K, Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev Vaccines. 2009;8:1183–93.

23. Fukushima T, Sekeue S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Kreig AM, McGhee JR, Fujihashi K. A recombinant of Flt3 ligand and Cpg ODN as nasal adjuvant elicits NALT dendritic cells for enhanced mucosal immunity. J Immunol. 2006;176:121–9.

24. Kataoka K, Fukushima Y, Briles DE, Miyake T, Fujihashi K, Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae. Microbiol Immunol Microbiol Immunol. 2017;61:195–205.

25. Challacombe SJ. Immunology of Diseases of the Oral Cavity. In: Mestecky J, editor. Mucosal Immunology. 4th ed. Oxford: Elsevier; 2015. p. 1943–84.

26. Ebersoile JL, Taubman MA, Smith DM, Frey DE. Human responses to Porphyromonas gingivalis and its lipopolysaccharide before and following therapy in rapidly progressive periodontitis patients. J Periodontol. 1992;63:1507–11.

27. Chen HA, Johnson BD, Sims TJ, De Strooper B, Persson GR. Periodontal complications with age. Periodontol 2000. 2018;78:185–94.

28. Kinoshita M, Yokote K, Arai H, Iida H, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daish H, Tsukamoto K, Deguchi J, Doshi S, Dobashi K, Hamaguchi H, Har A, Hiro T, Biro S, Fujikyo Y, Manamayo C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakagi H, Watsuki Y, Yanashita S, Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846–894.

29. Yoon YS, Jin M, Sin DD. Accelerated lung aging and chronic obstructive pulmonary disease. Expert Rev Respir Med. 2019;13:81–12.

30. Edowan JH, Perry G, Talmadge JE, Agrawal DK. Flt3-ligand reverses late allergic responses and airway hyper-responsiveness in a mouse model of allergic inflammation. J Immunol. 2004;172:5016–23.

31. Kutzler MA, Weiser DB. Developing DNA vaccines that call to dendritic cells. Clin Immunol. 2004;114:1241–1.

32. Marakovsky E, Brasel K, Topp M, Roux EP, Lyman SD, Shortman K, McKenna HJ. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 2002;195:153–62.

33. Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Hollingshead SK, Briles DE, Fujihashi K. Secretory-IgA plays an important role in the immunity to Streptococcus pneumoniae. J Immunol. 2010;185:1755–62.

34. Fukuyama Y, Ikeda Y, Ohori J, Sugita G, Aso K, Fujihashi K, Briles DE, McGhee JR, Fujihashi K. A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly. Immune Netw. 2015;15:9–15.

35. Asamura H, Tsuchida N, Sekeue S, Fukuyama Y, Tokuohara D, Gilbert RS, Fukuiwa T, Fujihashi K, Sata T, Tashiro M, Fujihashi K. A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine. 2012;30:803–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions